Protocol Ledger

NCT06500689 · Phase III · COMPLETED

To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

Interventional Phase III clinical trial protocol NCT06500689 sponsored by Shenzhen Salubris Pharmaceuticals Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-30 Enrollment: 366 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06500689
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)366 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06500689
Protocol FieldVerified Registry Value
NCT IdentifierNCT06500689
Consolidated Lead SponsorShenzhen Salubris Pharmaceuticals Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment366 participants (ACTUAL)
Registered Start Date2021-12-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI